Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jun 3, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding what factors might help patients with nephrotic syndrome—specifically those with a certain genetic risk factor called the APOL1 variant—achieve remission, which means their symptoms improve or disappear. The study will look at patients who have been diagnosed with two specific types of kidney damage, called minimal change disease or focal segmental glomerulosclerosis. Researchers will also explore how well corticosteroids, a type of medication, work in helping patients recover and whether these medications have any side effects.

To be eligible for this study, participants must be adults who have been treated in one of six nephrology centers between January 2016 and June 2024. They need to have a certain level of protein and a specific condition called hypoalbuminemia (low albumin levels in the blood) at the time of their kidney diagnosis. It's important to note that individuals with certain other kidney conditions or who do not wish to have their medical data used in research will not be included. While the trial is not yet recruiting participants, those who qualify will help researchers gather valuable information to improve treatment for nephrotic syndrome.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients followed in 6 nephrology centers between 01/01/2016 and 01/06/2024.
• • With characterization of APOL1 gene risk status
• • Proteinuria/creatinuria ratio \> 3 g/g at diagnosis of renal disease (within 48 hours of the diagnostic renal biopsy)
• • Hypoalbuminemia \< 30 g/L at diagnosis of renal disease (within 48 h of diagnostic renal biopsy)
• • Minimal change disease or segmental and focal hyalinosis lesions on renal biopsy.
• Exclusion Criteria:
• • Presence of diffuse deposits of immunoglobulins or complement fractions on immunofluorescence study
• • Presence of endo- or extracapillary hypercellular lesions on light microscopy
• • Opposition to the use of medical data